Mangoceuticals公司今日披露，其已针对MGX-0024抗病毒技术向《专利合作条约》提交国际专利申请。最新专利范围扩展至抑制动物或禽类通过呼吸道或口腔途径获得的病毒感染，标志着该技术在跨界病原体防控领域取得关键突破。
此次专利升级凸显了MGX-0024技术平台的多靶点应用潜力。相较于传统单一物种抗病毒方案，该技术能同步应对禽类与哺乳动物的气溶胶传播及消化道感染风险，为养殖业与野生动物保护提供创新解决方案。
专利文件显示，MGX-0024通过干扰病毒包膜蛋白与宿主细胞受体的结合机制，阻断跨物种传播链。实验数据证实其对禽流感、猪呼吸道冠状病毒等常见人畜共患病原体具有显著抑制效果，且未观测到细胞毒性反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.